Replies to post #221598 on Biotech Values

[DewDiligence]

(AMGN)—We're seeing the beginning of the end of the US rebating system. I predict that rebates will be effectively gone from the market by 2022, if not sooner.

[DewDiligence]

SNY/REGN cut Praluent’s US list price 60%—matching AMGN’s 2018 action on Repatha:

https://www.prnewswire.com/news-releases/regeneron-and-sanofi-offer-praluent-alirocumab-at-a-new-reduced-us-list-price-300792853.html